UroGen Pharma Ltd. (URGN): Shareholders' Equity
-$105.47M
As of 2025-12-31
-$132.40M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$105.47M | n/m | 2026-03-02, Balance as of period end |
| 2024-12-31 | -$8.80M | n/m | 2026-03-02, Balance as of period end |
| 2023-12-31 | -$65.21M | n/m | 2025-03-10, Balance as of period end |
| 2022-12-31 | -$89.36M | n/m | 2024-03-14, Balance as of period end |
| 2021-12-31 | $8.41M | -91.3% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $96.36M | -46.6% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $180.30M | +100.1% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $90.09M | +31.5% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $68.52M | +320.2% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $16.31M | +0.2% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $16.28M | n/a | 2018-03-15, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$105.47M | n/m |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $296.72M | +69.0% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $154.66M | +289.9% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $268.50M | -20.7% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $106.03M | +67.5% |
| Xencor Inc (XNCR) | 2025-12-31 | $635.59M | -6.2% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $198.82M | -7.9% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $1.34M | -88.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$659.62M | n/m |
Compare URGN, TBPH, ZVRA, ZYME side by side · Screen every company in Pharmaceutical Preparations ↗